

10 January 2022

Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")

Publication of New Research

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to inform shareholders that a new research note on the Company has recently been published by Pitt Street Research.

The research can be found on the Company's website via the link below:

<https://www.roquefortinvest.com/research-reports>

ENDS

Enquiries:

Roquefort Therapeutics plc

Stephen West (Chairman) +44 (0)20 3290
9339

Buchanan (Public Relations)

Ben Romney / Jamie Hooper / George Beale +44 (0)20 7466
5000

Optiva Securities Limited (Broker)

Christian Dennis +44 (0)20 3411
1881

For further information on Roquefort Therapeutics, please visit
www.roquefortinvest.com and @roquefortinvest on Twitter.

LEI: 254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company's wholly owned subsidiary, Lyramid Pty Ltd ("Lyramid"), is a pre-clinical biotech company focused on developing first in class Midkine inhibiting RNA therapeutics drugs for the treatment of cancer,

chronic inflammatory, autoimmune disorder and COVID-19. Recent progress within mRNA therapeutics has led to a reduction in drug development timelines and costs, increasing the chance of early value creation.

Through extensive research resulting in validation through publication in over 1,000 scientific journals, Lynamid has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lynamid holds the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Lynamid's pre-clinical programme is currently underway with an initial focus on cancer (including immunotherapy resistance) and COVID-19.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFZGGMNNLGZZM

Anonymous (not verified)

Publication of New Research

32379747

A

Mon, 01/10/2022 - 08:00

LSE RNS

Company Announcement - General

ROQ